CoreAge Rx publishes NAD+ injectable and nasal offers alongside semaglutide and tirzepatide pages. Seeing those products in one catalog can make them look like parts of a single wellness plan. The useful comparison starts by keeping each prescription’s purpose, evidence, price and renewal terms in its own record.
NAD Atlas checked the public product, offer, policy and support pages on October 15–16, 2026. CoreAge Rx receives commercial placement on this publication, disclosed in the feature below. This review reports source findings and unresolved questions; we did not enroll, order treatment, test a product or measure patient outcomes.
Treat NAD+ and GLP-1 care as separate clinical and purchase records. Confirm the selected quote and resolve conflicting refund wording before paying.
Semaglutide and tirzepatide have separate starting figures. No combined quote or selected prescription was verified.
The catalog contains different kinds of treatment
The NAD+ injectable and nasal pages market energy and related wellness goals. The semaglutide and tirzepatide pages describe weight care. Those are provider descriptions of separate offers, not evidence that adding NAD+ improves the outcome of a GLP-1 prescription.
Ask the clinician to identify the exact preparation, its intended purpose and the evidence for any proposed addition. An injectable and a nasal preparation are also different routes; a familiar ingredient name does not establish equivalent delivery or clinical results. Our existing NAD+ review supplies the earlier product-focused context.
The NAD+ pages do not display one consistent entry price
The checked NAD+ product pages displayed a starting figure of $93 per month. The separate offer page displayed $99, alongside multi-month savings language. We have not treated those pages as one confirmed transaction or chosen the lower number as the price every reader can obtain.
Request the selected route, quantity, treatment period, amount due now and renewal charge together. A starting figure may omit the details needed to compare two prescriptions. The discrepancy is a reason to obtain a written quote, not a basis to infer that either page establishes an all-in combined-care price.
Weight medicine needs its own quote
The semaglutide product page displayed a starting $79 monthly figure and the tirzepatide page displayed $129. Both pages advertise no membership fee. Those statements do not establish the cost of every dose, a particular supply or a combined NAD+ and weight-care order.
Do not add two headline rates and present the result as a provider-approved package. Ask which charges apply to each selected prescription and whether tests, clinical review or other services are separately payable. The NAD+ cost guide now includes this example so readers can keep the actual payment period beside each amount.
Pharmacy access and ingredient claims have evidence limits
The product pages describe U.S. compounding and physician review. FDA explains that compounded drugs are not FDA-approved and do not undergo its premarket review for safety, effectiveness and quality. A provider’s licensed-pharmacy claim does not change that status.
The NAD+ offer contains patient ratings, timing claims and broader wellness language. We do not turn those into independently verified outcomes or a clinical score. A claim about one medicine or ingredient cannot establish that a different preparation—or a combination with another prescription—will produce the same result. Ask for evidence relevant to the exact clinical question.
Resolve the refund wording before payment
The NAD+ offer advertises a full refund if a prescription is not approved. The general refund policy instead says the refundable treatment or medication portion is returned after a finding of medical ineligibility, with an applicable $50–$100 consultation fee remaining nonrefundable once review has begun. We have not verified an offer-specific exception that reconciles those statements.
Ask which policy applies to your selected order and obtain that answer before paying. A free-review or full-refund headline should not be treated as overriding the detailed policy without confirmation. This review reports the difference and does not promise the most favorable interpretation or a particular refund outcome.
An unshipped order may already be final
The policy makes prescription sales final once the prescription is approved and transmitted to the pharmacy for fulfillment. It expressly says that this can apply before shipment. It also imposes a separate 30-calendar-day cutoff from purchase, including when requested documentation has not been completed, except where law requires otherwise.
An eligible earlier cancellation may still have a consultation fee deducted. Record the purchase date, outstanding information and order stage, and contact the provider promptly if you need clarification. Cancelling a subscription stops future renewals; it does not automatically reverse an order already made final under the policy.
Distinguish order processing, delivery and support
The policy describes approximately five to seven business days for an order when information is supplied promptly, and roughly two to three business days for delivery after pharmacy shipment. Those are different clocks. A shipping estimate cannot tell you how long a pending clinical review or missing-document request will take.
The contact page lists weekday support hours and a typical two-to-four-business-day response target. We did not test that target, and it is not a promise of immediate clinical assessment. Ask which channel handles prescribing questions, which handles an order and where urgent concerns should be directed.
Our assessment: compare the documented offers, then the selected plan
CoreAge publishes enough detail to identify several important decisions, including compounding status, separate starting prices and the point when orders become final. The price and refund differences between its offer and policy pages remain material questions for the selected transaction.
For a reader considering more than one service, the useful next document is a complete plan showing each prescription, clinical purpose, responsible clinician, pharmacy and charge. Commercial placement on NAD Atlas does not establish medical superiority. We have not verified individual eligibility, the final formula, fulfillment quality or evidence that combining these offers improves outcomes.
Sources & reading notes
Editorial source review updated October 16, 2026. Provider pages describe their own offers; inclusion does not verify a product or its results.
- CoreAge Rx: NAD+ injectable product page Provider advertising; $93 starting figure, not a complete combined-care quote. Checked October 15, 2026.
- CoreAge Rx: NAD+ nasal product page Separate administration route and provider claims. Checked October 15, 2026.
- CoreAge Rx: NAD+ offer page Offer displays $99 and a full-refund claim that differs from the general policy. Checked October 16, 2026; no checkout completed.
- CoreAge Rx: semaglutide product page Provider advertises a $79 starting monthly figure; not verified for every prescription or dose. Checked October 15, 2026.
- CoreAge Rx: tirzepatide product page Provider advertises a $129 starting monthly figure; separate from NAD+ offerings. Checked October 15, 2026.
- CoreAge Rx: refund, subscription and shipping policy Approval and pharmacy-transmission finality, 30-day cutoff, consultation fees and renewal terms. Checked October 15, 2026.
- CoreAge Rx: contact and response-time information Business-day support hours and stated response target; no response-time test. Checked October 15, 2026.
- FDA: Understanding the Risks of Compounded Drugs Compounded drugs are not FDA-approved and do not receive premarket review. Checked October 15, 2026.
Educational information, not individualized medical advice. We do not claim medical review or firsthand treatment experience. Read our review standards and commercial disclosure.